Ligand initiated with a Buy at BofA
BofA initiated coverage of Ligand (LGND) with a Buy rating and $244 price target Citing a portfolio of more than 100 high-value commercial and development assets, increasing needs for flexible, non-dilutive capital in the industry and a lean cost structure, the analyst contends that the biopharma royalty firm can continue to deliver on its “aggressive earnings targets.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
See Insiders’ Hot Stocks on TipRanks >>
Read More on LGND:
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
LAZARD, INC. <LAZ.N>: KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
LAZARD, INC. : KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
What Stocks Will Shine When the AI Bubble Bursts? John Rogers Says Look to Smucker's
GFL ENVIRONMENTAL INC. <GFL.TO>: CIBC CUTS TARGET PRICE TO C$77 FROM C$82
GFL ENVIRONMENTAL INC. : CIBC CUTS TARGET PRICE TO C$77 FROM C$82
Gold edges higher after hitting a two-month low
Crypto prices
More
